ROR1-Specific Antibody for Selective B-Cell Lymphoma Targeting

Solution Overview

Problem

Current antibody therapies for B-cell lymphomas, such as rituximab and alemtuzumab, target antigens expressed on both malignant and normal B cells, leading to immunosuppression and damage to healthy cells, with no commercial therapeutic antibody specifically recognizing malignant B cells without affecting normal cells.

Innovation Solution

Development of an antibody with specificity for the extracellular domain of ROR1, which is selectively expressed on malignant cells, including B-cell tumors, with complementarity determining regions (CDRs) having specific amino acid sequences, and an avidity for ROR1 of 1 nM or less, allowing for targeted therapy and diagnostics.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibody therapies target antigens expressed on both malignant and normal B cells (such as CD20 or CD52), then therapeutic efficacy against lymphoma is improved, but damage to healthy cells and immunosuppression worsen

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoiddamage to healthy cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by targeting ROR1, an antigen that is locally expressed (present) on malignant B cells but absent or minimally expressed on normal B cells. This localized expression pattern allows the antibody to selectively bind and exert therapeutic effects on tumor cells while sparing healthy cells, thereby resolving the contradiction between therapeutic efficacy and damage to healthy tissues

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the target population by identifying ROR1 as a marker specifically expressed on malignant B cells (including B-CLL and MCL) rather than on normal B cells. This segmentation enables the antibody therapy to distinguish between diseased and healthy cells, achieving selective targeting that improves efficacy while reducing off-target effects

Inventive Principle:

Principle #1Segmentation

2Adaptability or versatility

If existing antibody therapies are used for B-cell lymphomas, then treatment options are available, but immunosuppression and lack of specificity for malignant cells worsen

Engineering Contradiction:

Improvetreatment availabilityVSAvoidspecificity for malignant cells

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies local quality by targeting ROR1, an antigen that is locally expressed (present) on malignant B cells but absent or minimally expressed on normal B cells. This localized expression pattern allows the antibody to selectively bind and exert therapeutic effects on tumor cells while sparing healthy cells, thereby resolving the contradiction between therapeutic efficacy and damage to healthy tissues

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the target parameter from previously used antigens (CD20, CD52) to ROR1, which has different expression characteristics. By selecting an antigen with distinct expression patterns (ROR1 on malignant cells only), the therapy achieves improved specificity while maintaining treatment availability for B-cell lymphomas

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP2421899B1Anti-human ROR1 antibodies

Publication Date: 2016.06.08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Figure 1
Figure 2A~2B
Figure 3

AI summary

The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.